Home > Insider Trading > Filing (0001127602-10-007208)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1022079	Quest Diagnostics Inc	DGX	Services-Medical Laboratories (8071)	161387862

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222676	Robert Hagemann	C/O Quest Diagnostics Incorporated 3 Giralda Farms Madison NJ 07940	Svp & Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-03-01	3,571	$24.76	107,245	No	4	M	Direct
Common Stock	Disposition	2010-03-01	3,571	$57.17	103,674	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2010-03-01	3,571	$0.00	3,571	$24.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
21,429	2006-02-13	2013-02-13	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,745	Indirect	SDCP

Footnotes

The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
These underlying shares were acquired on a periodic basis by the trustee of the Company's Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a recent date. The number of shares is based on the account balance of the Company stock fund under the plan (which includes some money market instruments), divided by the market price of the Company's stock as of that date.
The option vests in three equal annual installments beginning on the first annual anniversary of the grant date.
The exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 3, 2010.